Acusphere revenues and losses increase in Q3
Acusphere reported unaudited increased revenues and losses for the fiscal 2007 third quarter (end-Sept. 30).
For the quarter, the Watertown, Mass.-based company recognized $667,000 in revenue during the third quarter of 2007, compared to $12,000 in revenue in the same quarter last year.
The company attributed the increase in revenue to its agreement with the Swiss pharmaceutical company Nycomed for European marketing rights for Imagify, an ultrasound contrast agent designed to screen for coronary heart disease.
Acusphere also reported a net loss after dividends for the third quarter of 2007 of $14.6 million, compared to a net loss of $13.3 million in the prior year period.
For the quarter, the Watertown, Mass.-based company recognized $667,000 in revenue during the third quarter of 2007, compared to $12,000 in revenue in the same quarter last year.
The company attributed the increase in revenue to its agreement with the Swiss pharmaceutical company Nycomed for European marketing rights for Imagify, an ultrasound contrast agent designed to screen for coronary heart disease.
Acusphere also reported a net loss after dividends for the third quarter of 2007 of $14.6 million, compared to a net loss of $13.3 million in the prior year period.